

John A Bridgewater

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2005538/publications.pdf>

Version: 2024-02-01

92
papers

17,151
citations

61984

43
h-index

54911

84
g-index

98
all docs

98
docs citations

98
times ranked

14760
citing authors

#	ARTICLE	IF	CITATIONS
1	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGFR Aberrations: A Phase I Dose-Expansion Study. <i>Cancer Discovery</i> , 2022, 12, 402-415.	9.4	119
2	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	1.6	65
3	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. <i>ESMO Open</i> , 2022, 7, 100417.	4.5	3
4	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	12.1	11
5	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021, 26, e669-e678.	3.7	15
6	Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". <i>British Journal of Cancer</i> , 2021, 124, 679-680.	6.4	0
7	Targeting FGFR inhibition in cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2021, 95, 102170.	7.7	85
8	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2021, 22, 690-701.	10.7	396
9	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
10	Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. <i>Cancer Research</i> , 2021, 81, CT010-CT010.	0.9	28
11	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.1	194
12	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	6.3	90
13	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	7.7	73
14	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	6.4	37
15	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	2.4	96
16	Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes—The University College London Hospital (UCLH) Experience. <i>Cancers</i> , 2020, 12, 3545.	3.7	9
17	Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095680.	3.2	29
18	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020, 12, 2375.	3.7	2

#	ARTICLE	IF	CITATIONS
19	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2020, 21, 796-807.	10.7	620
20	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2518.	1.6	92
21	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 765-775.	8.1	33
22	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
23	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020, 123, 709-713.	6.4	20
24	Hepatic metastases resection after cetuximab: are we missing something? – Authors' reply. <i>Lancet Oncology, The</i> , 2020, 21, e229.	10.7	1
25	Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?. <i>Annals of Oncology</i> , 2020, 31, 447-448.	1.2	2
26	Systemic therapies for intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 72, 353-363.	3.7	235
27	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 398-411.	10.7	152
28	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1760-1768.	6.4	14
29	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.7	25
30	FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring <i>FGFR2</i> gene fusions or other rearrangements.. <i>Journal of Clinical Oncology</i> , 2020, 38, 108-108.	1.6	61
31	Systemic treatment of biliary tract cancer: now we have the evidence. <i>Annals of Oncology</i> , 2019, 30, 1851-1852.	1.2	0
32	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 854-862.	8.1	47
33	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	10.7	50
34	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	8.1	51
35	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2019, 20, 663-673.	10.7	773
36	Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment. <i>European Radiology</i> , 2019, 29, 3889-3900.	4.5	20

#	ARTICLE	IF	CITATIONS
37	ABC-06 A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. Journal of Clinical Oncology, 2019, 37, 4003-4003.	1.6	166
38	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring <i>FGFR2</i> gene rearrangements.. Journal of Clinical Oncology, 2019, 37, TPS468-TPS468.	1.6	6
39	Adjuvant therapy for resected gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 39-39.	1.2	7
40	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-88.	2.8	20
41	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. Health Technology Assessment, 2019, 23, 1-270.	2.8	34
42	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2018, 19, 562-578.	10.7	133
43	A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08). Annals of Oncology, 2018, 29, viii259.	1.2	6
44	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 2018, 119, 27-35.	6.4	19
45	How should we drain malignant obstruction at the liver hilum?. The Lancet Gastroenterology and Hepatology, 2018, 3, 657-658.	8.1	2
46	PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open, 2018, 3, e000379.	4.5	20
47	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Tj ETQq1 1 0.784314 rgBT /Overdo	2.8	31
48	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 2017, 12, 97-109.	3.6	56
49	The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy. Radiotherapy and Oncology, 2017, 125, 154-159.	0.6	30
50	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer, 2017, 17, 262.	2.6	16
51	Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision. BMC Cancer, 2017, 17, 365.	2.6	1
52	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. Journal of Clinical Oncology, 2017, 35, 4006-4006.	1.6	142
53	Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget, 2017, 8, 93856-93866.	1.8	42
54	Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e194-e203.	3.8	126

#	ARTICLE	IF	CITATIONS
55	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British Journal of Cancer, 2016, 114, 965-971.	6.4	39
56	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 2016, 115, 420-424.	6.4	9
57	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer, 2016, 16, 153.	2.6	62
58	Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Annals of Oncology, 2016, 27, 687-692.	1.2	82
59	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	1.2	88
60	Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT+C) in esophageal cancer.. Journal of Clinical Oncology, 2016, 34, 118-118.	1.6	1
61	Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma. Journal of Gastrointestinal Cancer, 2015, 46, 267-271.	1.3	13
62	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Annals of Oncology, 2015, 26, 702-708.	1.2	271
63	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. European Journal of Cancer, 2015, 51, 1694-1703.	2.8	25
64	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 967-978.	10.7	221
65	Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Annals of Oncology, 2015, 26, 1910-1916.	1.2	61
66	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 2015, 15, 564.	2.6	182
67	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology, 2014, 60, 1268-1289.	3.7	1,151
68	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 862-873.	10.7	239
69	Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncology, The, 2014, 15, e447-e460.	10.7	171
70	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals of Oncology, 2014, 25, 391-398.	1.2	314
71	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncology, The, 2014, 15, 601-611.	10.7	371
72	Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.. Journal of Clinical Oncology, 2014, 32, 3523-3523.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. Journal of Clinical Oncology, 2014, 32, 3556-3556.	1.6	3
74	Analysis of progression-free survival in the new EPOC study in an "œall wild-type" population.. Journal of Clinical Oncology, 2014, 32, 3566-3566.	1.6	1
75	ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).. Journal of Clinical Oncology, 2014, 32, 4002-4002.	1.6	3
76	Efficacy and safety of cisplatin and gemcitabine (CG) chemotherapy for advanced biliary tract cancer (ABC) in jaundiced patients (pts).. Journal of Clinical Oncology, 2014, 32, 294-294.	1.6	0
77	Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-related quality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial.. Journal of Clinical Oncology, 2014, 32, 4126-4126.	1.6	0
78	Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4025-4025.	1.6	3
79	ABC-04: A phase 1b trial of cisplatin, gemcitabine, and selumetinib in patients with advanced biliary tract cancer.. Journal of Clinical Oncology, 2014, 32, 4090-4090.	1.6	0
80	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.. Journal of Clinical Oncology, 2014, 32, TPS3653-TPS3653.	1.6	0
81	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. Journal of Clinical Oncology, 2014, 32, 3549-3549.	1.6	0
82	Outcome of second-line chemotherapy for biliary tract cancer. European Journal of Cancer, 2013, 49, 1511.	2.8	45
83	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncology, The, 2013, 14, 627-637.	10.7	346
84	Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Annals of Oncology, 2012, 23, 298-304.	1.2	79
85	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, The, 2011, 377, 2103-2114.	13.7	876
86	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine, 2010, 362, 1273-1281.	27.0	3,370
87	Photodynamic therapy for biliary tract cancer. British Journal of Surgery, 2009, 96, 225-226.	0.3	4
88	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study "œ The UK ABC-01 Study. British Journal of Cancer, 2009, 101, 621-627.	6.4	243
89	Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British Journal of Cancer, 2008, 98, 1425-1430.	6.4	96
90	New advances in the management of biliary tract cancer. Hpb, 2007, 9, 104-111.	0.3	9

#	ARTICLE	IF	CITATIONS
91	Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 2004, 350, 2343-2351.	27.0	3,268
92	Reply to J. Edeline et al. Journal of Clinical Oncology, 0, , .	1.6	1